Exhibit 1.01
Meridian Bioscience, Inc.
Conflict Minerals Report
For the Year Ended December 31, 2021
FORWARD-LOOKING STATEMENTS
Forward-looking statements contained in this Conflict Minerals Report (“Report”) are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. Statements in this Report which express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements, including statements related to the Company’s compliance efforts and expected actions identified in this Report. These forward-looking statements are subject to various risks, uncertainties and assumptions, including, among other matters, the Company’s customers’ requirements to use certain suppliers, the Company’s suppliers’ responsiveness and cooperation with the Company’s due diligence efforts, the Company’s ability to implement improvements in its conflict minerals program and the Company’s ability to identify and mitigate related risks in its supply chain. If one or more of these or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risk factors, see the Company’s other filings with the Securities and Exchange Commission (“SEC”), including its Annual Report on Form 10-K, filed with the SEC on November 23, 2021, and subsequent Quarterly Reports on Form 10-Q. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them unless otherwise required by law.
Company Overview
This is the Report for Meridian Bioscience, Inc. (“Meridian” or “the Company”) for the calendar year ended December 31, 2021 (“the Reporting Period”) in accordance with Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act (“Section 1502”) and Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”) (collectively, “the Rule”), that requires Meridian to perform certain procedures and disclose information about the use and origin of “conflict minerals” if these minerals are deemed to be necessary to the functionality or production of a product manufactured, or contracted to be manufactured. The minerals covered by these rules are commonly referred to as conflict minerals and include tin, tantalum, tungsten and gold (collectively, “3TG”).
Meridian is a fully-integrated life science company with principal businesses in: (i) the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and (ii) the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, various Polymerase Chain Reaction (“PCR”) master mixes, and bioresearch reagents used by other diagnostic manufacturers and researchers. Our reportable segments are Diagnostics and Life Science.
Products Overview
Our Diagnostics segment product portfolio includes just under 200 diagnostic tests and transport media, and is marketed to acute care hospitals, reference laboratories, outpatient clinics and physician offices in over 70 countries around the world. Our testing platforms include: Real-time PCR Amplification (revogene® brand); Isothermal DNA Amplification (Alethia® brand); Lateral Flow Immunoassay using fluorescent chemistry (Curian® brand); Rapid Immunoassay (ImmunoCard® and ImmunoCard STAT!® brands); Enzyme-linked Immunoassay (PREMIER® brand); Anodic Stripping Voltammetry (LeadCare® brands); and urea breath testing for H. pylori (BreathID® and BreathTek® brands).
Our Life Science segment develops, manufactures, sells and distributes bulk antigens, antibodies, immunoassay blocking reagents, specialized PCR master mixes, isothermal reagents, enzymes, nucleotides, and bioresearch reagents used predominantly by in vitro device (“IVD”) manufacturing companies, and to a lesser degree, by researchers and non-human clinical customers such as veterinary, food and environmental. Our Life Science segment products are marketed to IVD manufacturing customers as a source of raw materials for their human